Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
about
Role of endoglin in fibrosis and sclerodermaPharmacology and rationale for imatinib in the treatment of sclerodermaA non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.Deletion of 4q28.3-31.23 in the background of multiple malformations with pulmonary hypertension.CCN2 is required for the TGF-β induced activation of Smad1-Erk1/2 signaling networkL-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction.Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levelsEndoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.Establishment and characterization of scleroderma fibroblast clonal cell lines by introduction of the hTERT gene.Fli1 is a negative regulator of estrogen receptor α in dermal fibroblastsThe impact of Fli1 deficiency on the pathogenesis of systemic sclerosisThe primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.Transforming growth factor beta as a therapeutic target in systemic sclerosis.Noncanonical transforming growth factor beta signaling in scleroderma fibrosisUnderstanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.Fibroblast abnormalities in the pathogenesis of systemic sclerosis.Cell-type-specific differentiation and molecular profiles in skin transplantation: implication of medical approach for genetic skin diseases.The Role of TGF-β Receptors in Fibrosis.New renal drug development to face chronic renal disease.Cytokines in the immunopathology of systemic sclerosis.Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta.Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations.Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive Alk1/Smad1 activation.Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.Fell-Muir lecture: Connective tissue growth factor (CCN2) -- a pernicious and pleiotropic player in the development of kidney fibrosis.Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.Human Fibrotic Diseases: Current Challenges in Fibrosis Research.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
P2860
Q26821836-4DE70FEC-CFC1-4695-AB09-93F421B8A208Q26825153-0243582C-0922-4E12-BD7B-4D842124956FQ33551475-DB0AAF9B-841C-4ECB-BFE4-EB400B91CE6FQ33791395-802A3ADD-0191-43B6-8CC3-6A8F6964DAF8Q33961583-F3A2F787-47BD-46F0-A4ED-57CC94C324A7Q34338572-43E1560C-7FB4-45DC-B75E-FDAD74D1EF29Q34555185-01A0C280-E49A-4969-B2A9-3BB0760808C7Q36054237-8F973B0F-729E-4629-BF0A-A6439F3C0C47Q36054245-237968A1-BA73-431A-9222-54CABDC91320Q36795578-D702EE68-DBDE-4FEC-8892-23ABB0279A21Q37294366-60F8B10F-9A14-4B05-A896-A7DE8AF01984Q37301981-82C66489-7E0B-4F59-9186-90F33A972706Q37305155-5BCF2281-8972-4EDB-877F-43C92D22ADB8Q37413166-4F3CF9CD-3A51-47A3-9175-144024659011Q37428739-AC1346D8-A976-4E31-9420-3515CC7A9835Q37588466-5C93E710-0716-4490-8E7B-9EC969164A12Q37638268-C620EC6D-4173-49B3-BF11-779A61E36C61Q37768336-44FE1928-9570-48CE-B7A6-463705AD0319Q37905795-3A169596-7B3B-4FE2-A0B1-17D0BEBFA3FEQ37969117-5AB4716B-24CD-437C-AF9E-AB0B49533571Q38026846-E0FA390E-D081-4A0A-91E2-D33947723046Q38246640-A48A866B-F3A4-4614-8EAB-32D88D673BC5Q38543692-CD9D0C39-3AA2-4524-BE52-37B198C5AEB7Q38733768-814DBBC4-6CAB-41CD-88E9-D30BC30E4392Q39987550-61F26802-9B55-4EB8-B531-44EC55006B82Q41347489-00D85EAD-4D23-40C3-A529-C3A30B209CE5Q42243246-F8A5EE87-E3CF-4D5A-9D41-F6BB6C459E5EQ42486771-3146F21B-D23B-42F7-8D0B-31D9A3330515Q42501087-A84C527B-2608-403E-95F6-3C2ADFBD23F9Q43172936-DF2D339C-F917-4D31-9984-2A3D1B87515AQ43763309-2B1CE14C-87D8-42B5-B4BC-01097123CC61Q47718418-1A735DBB-B864-4FAD-A1A1-5A599242C868Q52536468-2DD50595-3F78-4BD6-9DEB-21F91E22A46EQ54546815-C3AB005D-B03E-4698-AF10-D923E23BF61CQ54595702-F99EE02A-014C-4A81-A3A3-AB1496CB5F14
P2860
Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@en
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@nl
type
label
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@en
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@nl
prefLabel
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@en
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@nl
P2093
P2860
P356
P1476
Smad1 pathway is activated in ...... targeted by imatinib mesylate.
@en
P2093
Edwin Smith
Jaspreet Pannu
Maria Blaszczyk
Peter ten Dijke
Sashidhar Nakerakanti
Stefania Jablonska
Yoshihide Asano
P2860
P304
P356
10.1002/ART.23698
P577
2008-08-01T00:00:00Z